Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Bowenoid Papulosis Medication

  • Author: Mary V Kaldas, MD; Chief Editor: Dirk M Elston, MD  more...
 
Updated: Sep 08, 2014
 

Medication Summary

Destruction of the lesion is the treatment of choice for bowenoid papulosis. Most medications act to some degree as both destructive and immunomodulating agents.

Next

Keratolytic agents

Class Summary

Inhibit cell proliferation by blocking the progression of the cell cycle at specific stages.

Podophyllum resin (Pod-Ben, Podocon-25, Podofin)

 

Topical treatment for benign growths including external genital and perianal warts, papillomas, and fibroids.

Arrests mitosis in metaphase; active agent is podophyllotoxin; type of podophyllum resin used determines strength. American podophyllum contains one fourth of the amount reported by an Indian source.

Trichloroacetic acid (Tri-Chlor)

 

Cauterizes skin, keratin, and other tissues. Although caustic, causes less local irritation and systemic toxicity than others in the same class; however, response often is incomplete and recurrence occurs frequently.

Imiquimod (Aldara)

 

Induces secretion of interferon alpha and other cytokines; mechanisms of action are unknown.

5-Fluorouracil cream (Efudex, Adrucil, Fluoroplex)

 

For treatment-resistant bowenoid papulosis. Interferes with DNA synthesis by blocking the methylation of deoxyuridylic acid, and inhibits thymidylate synthetase, which subsequently reduces cell proliferation.

Previous
 
 
Contributor Information and Disclosures
Author

Mary V Kaldas, MD Resident Physician in Anatomic Pathology, National Institutes of Health

Disclosure: Nothing to disclose.

Coauthor(s)

Mark P Eid, MD Founder and Director, Virginia Dermatology and Skin Surgery Center

Mark P Eid, MD is a member of the following medical societies: American Academy of Dermatology, American Medical Association, American Society for Dermatologic Surgery, Pennsylvania Academy of Dermatology

Disclosure: Nothing to disclose.

Specialty Editor Board

Michael J Wells, MD, FAAD Associate Professor, Department of Dermatology, Texas Tech University Health Sciences Center, Paul L Foster School of Medicine

Michael J Wells, MD, FAAD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, Texas Medical Association

Disclosure: Nothing to disclose.

Lester F Libow, MD Dermatopathologist, South Texas Dermatopathology Laboratory

Lester F Libow, MD is a member of the following medical societies: American Academy of Dermatology, American Society of Dermatopathology, Texas Medical Association

Disclosure: Nothing to disclose.

Chief Editor

Dirk M Elston, MD Professor and Chairman, Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina College of Medicine

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Additional Contributors

Mark W Cobb, MD Consulting Staff, WNC Dermatological Associates

Mark W Cobb, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Society of Dermatopathology

Disclosure: Nothing to disclose.

Acknowledgements

Edward A DiPreta, MD Dermatologist, DiPreta Dermatology

Edward A DiPreta, MD is a member of the following medical societies: American Academy of Dermatology, American Medical Association, American Society for MOHS Surgery, and Medical Association of Georgia

Disclosure: Nothing to disclose.

Kurt Maggio, MD Director of Dermatologic Surgery and Cutaneous Oncology, Assistant Chief, Department of Dermatology, Walter Reed Army Medical Center

Disclosure: Nothing to disclose.

References
  1. Zhou L, Kang D, Xu C, Zhao W, Tian B, Chen L. Expression of cyclin D1 and cyclin E significantly associates with human papillomavirus subtypes in Bowenoid papulosis. Acta Histochem. 2013 May. 115(4):339-43. [Medline].

  2. Halasz C, Silvers D, Crum CP. Bowenoid papulosis in three-year-old girl. J Am Acad Dermatol. 1986 Feb. 14(2 Pt 2):326-30. [Medline].

  3. Godfrey JC, Vaughan MC, Williams JV. Successful treatment of bowenoid papulosis in a 9-year-old girl with vertically acquired human immunodeficiency virus. Pediatrics. 2003 Jul. 112(1 Pt 1):e73-6. [Medline].

  4. Feng J, Wu F, Liu F, Deng D, Chen J, Zeng M, et al. Spontaneous regression of bowenoid papulosis. Dermatol Online J. 2013 May 15. 19(5):18185. [Medline].

  5. Rüdlinger R, Grob R, Yu YX, Schnyder UW. Human papillomavirus-35-positive bowenoid papulosis of the anogenital area and concurrent human papillomavirus-35-positive verruca with bowenoid dysplasia of the periungual area. Arch Dermatol. 1989 May. 125(5):655-9. [Medline].

  6. Fader DJ, Stoler MH, Anderson TF. Isolated extragenital HPV-thirties-group-positive bowenoid papulosis in an AIDS patient. Br J Dermatol. 1994 Oct. 131(4):577-80. [Medline].

  7. Johnson TM, Saluja A, Fader D, et al. Isolated extragenital bowenoid papulosis of the neck. J Am Acad Dermatol. 1999 Nov. 41(5 Pt 2):867-70. [Medline].

  8. Kratochvil FJ, Cioffi GA, Auclair PL, Rathbun WA. Virus-associated dysplasia (bowenoid papulosis?) of the oral cavity. Oral Surg Oral Med Oral Pathol. 1989 Sep. 68(3):312-6. [Medline].

  9. Lee HJ, Shin DH, Choi JS, Kim KH. A case of isolated bowenoid papulosis of the nipple. Ann Dermatol. 2014 Jun. 26(3):381-4. [Medline]. [Full Text].

  10. Dubina M, Goldenberg G. Viral-associated nonmelanoma skin cancers: a review. Am J Dermatopathol. 2009 Aug. 31(6):561-73. [Medline].

  11. Xu X, Erickson L, Chen L, Elder DE. Diseases Caused by Viruses. Lever's Histopathology of Skin. 10th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2009. 65-7.

  12. Kazlouskaya V, Shustef E, Allam SH, Lal K, Elston D. Expression of p16 protein in lesional and perilesional condyloma acuminata and bowenoid papulosis: clinical significance and diagnostic implications. J Am Acad Dermatol. 2013 Sep. 69(3):444-9. [Medline].

  13. Shimizu A, Kato M, Ishikawa O. Bowenoid papulosis successfully treated with imiquimod 5% cream. J Dermatol. 2014 Jun. 41(6):545-6. [Medline].

  14. Goorney BP, Polori R. A case of Bowenoid papulosis of the penis successfully treated with topical imiquimod cream 5%. Int J STD AIDS. 2004 Dec. 15(12):833-5. [Medline].

  15. Lucker GP, Speel EJ, Creytens DH, et al. Differences in imiquimod treatment outcome in two patients with bowenoid papulosis containing either episomal or integrated human papillomavirus 16. J Invest Dermatol. 2007 Mar. 127(3):727-9. [Medline].

  16. Orengo I, Rosen T, Guill CK. Treatment of squamous cell carcinoma in situ of the penis with 5% imiquimod cream: a case report. J Am Acad Dermatol. 2002 Oct. 47(4 Suppl):S225-8. [Medline].

  17. Ricart JM, Cordoba J, Hernandez M, Esplugues I. Extensive genital bowenoid papulosis responding to imiquimod. J Eur Acad Dermatol Venereol. 2007 Jan. 21(1):113-5. [Medline].

  18. Shastry V, Betkerur J, Kushalappa. Bowenoid papulosis of the genitalia successfully treated with topical tazarotene: a report of two cases. Indian J Dermatol. 2009 Jul. 54(3):283-6. [Medline]. [Full Text].

  19. Lim JH, Lim KS, Chong WS. Dramatic Clearance of HIV-Associated Bowenoid Papulosis Using Combined OralAcitretin and Topical 5% Imiquimod. J Drugs Dermatol. 2014 Aug 1. 13(8):901-902. [Medline].

  20. Bourgault Villada I, Moyal Barracco M, Berville S, et al. Human papillomavirus 16-specific T cell responses in classic HPV-related vulvar intra-epithelial neoplasia. Determination of strongly immunogenic regions from E6 and E7 proteins. Clin Exp Immunol. 2010 Jan. 159(1):45-56. [Medline]. [Full Text].

  21. Champion RH, Burton JL, Burns DA. Rook/Wilkinson/Ebling Textbook of Dermatology. 6th ed. London, UK: Blackwell Science; 1998. Vols 1-2: 1047, 1676, 3197-8, 3233.

  22. de Belilovsky C, Lessana-Leibowitch M. [Bowen's disease and bowenoid papulosis: comparative clinical, viral, and disease progression aspects]. Contracept Fertil Sex. 1993 Mar. 21(3):231-6. [Medline].

  23. Grekin RC, Samlaska CP, Vin Christian K. Andrews Diseases of the Skin. 9th ed. Philadelphia, Pa: WB Saunders; 2000. 515.

  24. Schwartz RA, Stoll HL. Epithelial precancerous lesions. Freedberg IM, Fitzpatrick T, eds. Fitzpatrick's Dermatology in General Medicine. 5th ed. New York, NY: McGraw-Hill; 1999. Vol 1: 831-2.

 
Previous
Next
 
Bowenoid papulosa histopathology (hematoxylin and eosin, magnification 40X).
Bowenoid papulosa histopathology (hematoxylin and eosin, magnification 400X).
Typical appearance of bowenoid papulosis in the female.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.